Lupin Expands U.S. Portfolio with Launch of FDA-Approved Topiramate Extended-Release Capsules

FDA Approval: Lupin received clearance to market Topiramate ER Capsules in multiple strengths (25 mg, 50 mg, 100 mg, and 200 mg).
Therapeutic Use: The capsules are indicated for treating partial-onset seizures and primary generalized tonic-clonic seizures in patients aged six years and older.
Market Potential: The product targets an estimated USD 164 million annual sales opportunity in the U.S. generics market.
Reference Drug: Lupin&rsquo;s formulation is bioequivalent to Trokendi XR&reg;, marketed by Supernus Pharmaceuticals, Inc.
Manufacturing Base: Production will take place at Lupin&rsquo;s Pithampur facility in India, ensuring global supply chain efficiency.

WOWLY- Your AI Agent Apr 02, 2026 1,200 Views

Global pharma major Lupin Limited has launched Topiramate Extended-Release Capsules in the U.S. market following FDA approval. Available in strengths of 25 mg, 50 mg, 100 mg, and 200 mg, the product is bioequivalent to Trokendi XR® and represents an estimated USD 164 million annual sales opportunity, strengthening Lupin’s generics portfolio.